NNG
H1 2026 report
Revenue
0 m PLN
— YoY
Net income
-6.54 m PLN
— YoY
EBITDA
-6.43 m PLN
— YoY
FCF
-13.36 m PLN
— YoY
Summary
Investment thesis
- Emisja akcji serii N (24,5 mln zł, marzec 2026) oraz brak jakiegokolwiek zadłużenia odsetkowego dają Grupie komfortową poduszkę płynnościową na najbliższe kwartały.
- Planowana akwizycja Auxilius Pharma S.A. (do 99,99% udziałów, transakcja bezgotówkowa, wycena NanoGroup 179 mln zł) może istotnie zmienić profil Grupy i strukturę akcjonariatu poprzez emisję do 26 mln nowych akcji serii O.
- Dofinansowanie grantowe (22,76 mln zł z FENG na NanOX 4 Kidney, plus ok. 6,86 mln zł rekomendowane we wrześniu 2026 na Bioadsorbery) ogranicza zależność od kolejnych emisji akcji.
- Biegły rewident zwrócił uwagę (paragraf objaśniający) na odstępstwo Zarządu od zalecenia KNF w sprawie ujmowania nakładów na System NanOX jako aktywa, a nie kosztu — to obszar wymagający własnej oceny inwestora.
Read the full analysis
Financial data is open to everyone. The full analysis — management verdict, commentary, risks, and the full narrative — is available after you sign up or log in.
Financials
BETA
NNG · H1 2026
| Metric | H1 2026 | H1 2025 | Δ YoY | YTD 2026 | Δ YoY | Value type | Segment | Conf. |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | — | — | 0 | — | reported | — | 1.00 |
| EBITDA | -6.43 | — | — | -6.43 | — | derived | — | 0.90 |
| EBIT | -6.69 | — | — | -6.69 | — | reported | — | 1.00 |
| EBT | -6.69 | — | — | -6.69 | — | reported | — | 1.00 |
| Net income | -6.54 | — | — | -6.54 | — | reported | — | 1.00 |
| EPS (basic) (PLN) | 0 | — | — | 0 | — | reported | — | 1.00 |
| EPS (diluted) (PLN) | 0 | — | — | 0 | — | reported | — | 1.00 |
| D&A | 0.26 | — | — | 0.26 | — | reported | — | 1.00 |
| Income tax | 0 | — | — | 0 | — | reported | — | 1.00 |
| Shares (basic) (m units) | 42.63 | — | — | — | — | reported | — | 1.00 |
| Cash | 8.04 | — | — | — | — | reported | — | 1.00 |
| Total debt | 0 | — | — | — | — | reported | — | 1.00 |
| Net debt | -8.04 | — | — | — | — | derived | — | 1.00 |
| Equity | 27.06 | — | — | — | — | reported | — | 1.00 |
| Total assets | 32.02 | — | — | — | — | reported | — | 1.00 |
| Current assets | 8.92 | — | — | — | — | reported | — | 1.00 |
| Current liabilities | 1.08 | — | — | — | — | reported | — | 1.00 |
| Non-current liabilities | 3.88 | — | — | — | — | reported | — | 1.00 |
| Inventory | 0.11 | — | — | — | — | reported | — | 1.00 |
| Trade payables | 0.77 | — | — | — | — | reported | — | 1.00 |
| CFO | -13.36 | — | — | -13.36 | — | reported | — | 1.00 |
| CapEx | 0 | — | — | 0 | — | reported | — | 0.50 |
| FCF | -13.36 | — | — | -13.36 | — | derived | — | 0.50 |
| Current ratio | 8.26x | — | — | — | — | derived | — | 1.00 |
| Quick ratio | 8.16x | — | — | — | — | derived | — | 1.00 |
| Cash ratio | 7.44x | — | — | — | — | derived | — | 1.00 |
| Debt / equity | 0x | — | — | — | — | derived | — | 1.00 |
| Debt / assets | 0x | — | — | — | — | derived | — | 1.00 |
| Net debt / equity | -0.3x | — | — | — | — | derived | — | 1.00 |
| EBITDA growth (YoY) | -47.53% | — | — | -47.53% | — | derived | — | 0.85 |
| EBIT growth (YoY) | -52.62% | — | — | -52.62% | — | derived | — | 1.00 |
| Net income growth (YoY) | -46.27% | — | — | -46.27% | — | derived | — | 1.00 |
| EPS growth (YoY) | -14.29% | — | — | -14.29% | — | derived | — | 1.00 |
H1 2026 · Δ YoY
Revenue
0
—
0
—
- H1 2025
- —
- YTD 2026
- 0
- Δ YoY
- —
EBITDA
-6.43
—
-6.43
—
- H1 2025
- —
- YTD 2026
- -6.43
- Δ YoY
- —
EBIT
-6.69
—
-6.69
—
- H1 2025
- —
- YTD 2026
- -6.69
- Δ YoY
- —
EBT
-6.69
—
-6.69
—
- H1 2025
- —
- YTD 2026
- -6.69
- Δ YoY
- —
Net income
-6.54
—
-6.54
—
- H1 2025
- —
- YTD 2026
- -6.54
- Δ YoY
- —
EPS (basic)
(PLN)
0
—
0
—
- H1 2025
- —
- YTD 2026
- 0
- Δ YoY
- —
EPS (diluted)
(PLN)
0
—
0
—
- H1 2025
- —
- YTD 2026
- 0
- Δ YoY
- —
D&A
0.26
—
0.26
—
- H1 2025
- —
- YTD 2026
- 0.26
- Δ YoY
- —
Income tax
0
—
0
—
- H1 2025
- —
- YTD 2026
- 0
- Δ YoY
- —
Shares (basic)
(m units)
42.63
—
42.63
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Cash
8.04
—
8.04
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Total debt
0
—
0
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Net debt
-8.04
—
-8.04
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Equity
27.06
—
27.06
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Total assets
32.02
—
32.02
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Current assets
8.92
—
8.92
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Current liabilities
1.08
—
1.08
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Non-current liabilities
3.88
—
3.88
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Inventory
0.11
—
0.11
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Trade payables
0.77
—
0.77
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
CFO
-13.36
—
-13.36
—
- H1 2025
- —
- YTD 2026
- -13.36
- Δ YoY
- —
CapEx
0
—
0
—
- H1 2025
- —
- YTD 2026
- 0
- Δ YoY
- —
FCF
-13.36
—
-13.36
—
- H1 2025
- —
- YTD 2026
- -13.36
- Δ YoY
- —
Current ratio
8.26x
—
8.26x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Quick ratio
8.16x
—
8.16x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Cash ratio
7.44x
—
7.44x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Debt / equity
0x
—
0x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Debt / assets
0x
—
0x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Net debt / equity
-0.3x
—
-0.3x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
EBITDA growth (YoY)
-47.53%
—
-47.53%
—
- H1 2025
- —
- YTD 2026
- -47.53%
- Δ YoY
- —
EBIT growth (YoY)
-52.62%
—
-52.62%
—
- H1 2025
- —
- YTD 2026
- -52.62%
- Δ YoY
- —
Net income growth (YoY)
-46.27%
—
-46.27%
—
- H1 2025
- —
- YTD 2026
- -46.27%
- Δ YoY
- —
EPS growth (YoY)
-14.29%
—
-14.29%
—
- H1 2025
- —
- YTD 2026
- -14.29%
- Δ YoY
- —